ArticleBioscience reports2026
Differential glucose uptake response to IGF-II and vesiculin in insulin-resistant muscle and adipose cells.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Type 2 diabetes (T2D), a significant global health concern, is characterised by insulin resistance and progressive pancreatic β-cell degradation leading to failure of blood glucose regulation. Pancreatic islet hormones are essential for systemic glucose homeostasis, and their dysregulation is implicated in T2D pathogenesis. Characterisation of these hormones has been critical for understanding disease progression and designing therapeutic approaches. Vesiculin is a two-chain peptide derived from insulin-like growth factor-II (IGF-II) via a four-amino-acid excision. Studies of IGF-II and vesiculin revealed comparable insulin-like glucoregulatory activity in mice; however, in insulin-resistant animal models, vesiculin activity remains intact, whereas IGF-II activity is impeded, highlighting potential pharmacological relevance for vesiculin. We aimed to compare the glucoregulatory activity of vesiculin and IGF-II in differentiated 3T3-L1 adipocytes and L6-GLUT4myc myoblasts under insulin-sensitive and insulin-resistant conditions to understand tissue-specific activities of these peptides. Further, we characterised binding efficiency of vesiculin and IGF-II to several IGF-binding proteins (IGFBPs). Vesiculin exhibited glucose uptake comparable to IGF-II in both cell types, with similar dose response curves. Vesiculin retained efficacy in insulin-resistant myotubes, whereas IGF-II activity was blunted; however, both peptides were not significantly impacted by insulin resistance in adipocytes. Vesiculin also showed a modest synergistic effect with insulin in resistant adipocytes. Additionally, binding assays revealed that vesiculin had significantly lower affinity for IGFBP3 and IGFBP5 compared with IGF-II. These findings demonstrate that vesiculin exhibits a distinct glucoregulatory signalling profile from IGF-II, discernible specifically under insulin-resistant conditions despite their structural similarity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.